Prenetics (PRE) Q4 2025: IM8 Revenue Run Rate Hits $120M, Driving 480% Growth and Strategic Reset
Prenetics’ transformation into a consumer health pure-play is now fully evident as IM8’s explosive launch and operational discipline drove a 480% revenue surge and a clear path to profitability. The company’s divestitures, margin expansion, and recurring revenue model position it for accelerating global scale, while new product launches and localization efforts set up further upside into 2026. Investors should watch for execution on subscription growth, international traction, and leverage of a capital-rich balance sheet.
Summary
- IM8’s Subscription Model Locks in Predictable Growth: Recurring revenue and high customer retention anchor the business transition.
- Strategic Divestitures Sharpen Focus and Margin Profile: Asset sales and exit from non-core units solidify capital position and boost gross margin.
- Global Expansion and New SKUs Set Stage for 2026: Localization and upcoming launches are not yet in guidance, creating optionality for further upside.
Performance Analysis
Prenetics’ Q4 marked a decisive inflection point, with IM8, its premium consumer health supplement brand, delivering $27.4 million in Q4 revenue and pushing the company to a record $92.4 million for the full year, up 480% YoY. IM8’s annualized revenue run rate reached $120 million less than a year after launch, which management claims is among the fastest in the global supplement industry. The company’s consolidated gross margin improved to 59% in Q4, with IM8 alone generating a 63% gross margin, demonstrating the impact of focusing on higher-value, direct-to-consumer health products.
Operating leverage is now materializing, as adjusted EBITDA loss narrowed by over 70% YoY in Q4 and by 27% for the year, despite heavy marketing investment. The exit from low-margin businesses, including Europa and ACT Genomics, coupled with the sale of the Insighta stake, has further improved the company’s margin profile and left Prenetics with $171 million in liquidity and zero debt. Importantly, the company’s payback period on customer acquisition is just 3.4 months, and a shift to quarterly subscriptions has more than doubled average order value to $233 in early 2026, boosting cash flow and reducing churn risk.
- IM8 Drives Revenue and Margin Expansion: IM8 accounted for the majority of revenue and delivered gross margins above 60%, validating the pivot to premium health supplements.
- Recurring Revenue Foundation: 80% of new customers now opt for subscriptions, anchoring stable, predictable cash flows.
- Capital Efficiency and Operating Leverage: Rapid payback on marketing spend and cost discipline are accelerating the path to EBITDA profitability by Q4 2027.
With IM8’s international growth, a multi-channel marketing strategy, and new SKUs in the pipeline, Prenetics is now positioned as a high-growth, asset-light consumer health platform with significant operating leverage ahead.
Executive Commentary
"2025 was the most transformative year in our company's history. We achieved record revenue of 92.4 million, a 480% increase year over year, driven by the explosive launch of IM8, our premium consumer health brand co-founded with David Beckham... These moves have unlocked significant shareholder value, simplified our story, and fortified our financial position."
Danny Young, Chief Executive Officer and Co-Founder
"Total revenue in the fourth quarter surged 457% year-over-year to $36.6 million and increased 55% sequentially from Q3. This was driven by IMH, which contributed $27.4 million in Q4... We expect IMAG revenue of approximately 180 to 200 million for full year 2026, representing nearly 300% year-over-year growth. We are targeting a gross margin of approximately 60% in full year 2026."
Stephen Lowe, Chief Financial Officer
Strategic Positioning
1. Pure-Play Consumer Health Focus
Prenetics’ divestiture of three non-core assets in 2025-2026 has transformed the company into a focused consumer health platform, enabling all resources and capital to be deployed behind IM8. This has structurally improved the margin profile and simplified the investment case for new institutional coverage.
2. IM8 Brand Momentum and Recurring Revenue Engine
The IM8 brand, co-founded with David Beckham, has achieved rapid product-market fit, with 40% of revenue from the U.S. and 60% international, spanning 30 markets. The business now operates with 80% of new customers on subscription, and a blended LTV:CAC ratio of 3X, creating a robust, recurring revenue flywheel.
3. Data-Driven Customer Acquisition and AI Leverage
Prenetics utilizes AI-driven digital marketing to launch and test up to 1,000 new ads weekly, optimizing customer acquisition cost and scaling efficiently. The company’s approach to performance marketing has supported both rapid scale and capital efficiency, with payback periods under four months.
4. Global Expansion and Localization
Localization initiatives are underway in at least five new markets by Q2 2026, with management expecting a 10-15% uplift in local revenue from customized websites and campaigns. This international push is supported by strategic ambassador partnerships and a scientific advisory board to reinforce credibility across geographies.
5. Capital Allocation and Optionality
With $171 million in liquidity and no debt, Prenetics is positioned to fund organic growth, invest in new SKUs, and selectively consider M&A. Management’s stated preference is to build organically, leveraging its digital marketing flywheel, but remains open to strategic acquisitions if opportunities align.
Key Considerations
Prenetics’ Q4 results underscore a business model pivot that is now fully underway, with IM8’s high-margin, recurring revenue anchoring future growth and a capital-rich balance sheet providing both stability and optionality. Execution on international expansion, marketing channel diversification, and new product launches will be critical to sustaining momentum into 2026 and beyond.
Key Considerations:
- Quarterly Subscription Shift: The move to quarterly subscriptions more than doubled average order value and shortened payback, enhancing cash flow predictability.
- International Diversification: Revenue is well distributed across the U.S., Canada, UK, Australia, and Singapore, reducing reliance on any single geography.
- AI-Driven Marketing Scale: AI tools enable rapid ad testing and creative optimization, supporting efficient customer acquisition and scale.
- Balance Sheet Strength: Recent asset sales have fortified liquidity, providing ample runway for investment in growth and innovation.
- Upcoming Product Launches: Two new SKUs in large health supplement categories are planned for Q4 2026, offering potential incremental upside not yet in guidance.
Risks
Prenetics faces risks typical of high-growth consumer health platforms, including potential increases in customer acquisition costs as digital channels saturate, execution risk in international localization, and reliance on continued product-market fit for IM8. The company’s aggressive growth targets require sustained marketing efficiency and retention, while new product launches must deliver incremental growth without diluting brand equity. Regulatory scrutiny in supplements and evolving consumer preferences remain industry-wide watchpoints.
Forward Outlook
For Q1 2026, Prenetics guided to:
- Continued momentum in IM8 revenue, with Q1 tracking above Q4’s run rate.
- Ongoing margin expansion as low-margin legacy operations roll off.
For full-year 2026, management reaffirmed guidance:
- IM8 revenue of $180 to $200 million, representing nearly 300% YoY growth.
- Gross margin of approximately 60%.
- Adjusted EBITDA loss of $16 to $20 million, with a clear path to profitability by Q4 2027.
Management emphasized that guidance does not include revenue from two new SKUs launching in Q4 2026, nor the full impact of localization, suggesting upside potential if execution remains strong. Key drivers will be new customer acquisition, international expansion, and further marketing channel diversification.
Takeaways
Prenetics’ Q4 2025 results mark a structural pivot to a high-growth, capital-light, and margin-rich consumer health platform, with IM8’s subscription engine and global expansion as the core thesis. The company’s strong balance sheet and operational discipline provide a buffer against volatility and enable continued investment in growth levers.
- IM8’s Recurring Revenue Model: Subscription adoption and high retention rates underpin sustainable growth and cash flow visibility.
- Margin and Focus Gains from Divestitures: Selling non-core assets has sharpened strategic focus and improved profitability potential.
- Execution Watchpoints for 2026: Investors should monitor international localization, new SKU launches, and marketing efficiency as key sources of upside or risk.
Conclusion
Prenetics enters 2026 with momentum, a fortified balance sheet, and a focused growth strategy centered on IM8’s recurring revenue platform. The pivot to premium consumer health, combined with operational discipline and new product launches, positions the company for further scale, but the next phase will hinge on execution in customer acquisition, global expansion, and retention.
Industry Read-Through
Prenetics’ rapid pivot and IM8’s explosive growth highlight the power of direct-to-consumer models in the premium health supplement sector, particularly when anchored by celebrity partnerships and robust digital marketing. The success of a high-LTV subscription model and AI-driven marketing experimentation may serve as a blueprint for other supplement and wellness brands seeking scale and capital efficiency. Asset-light, recurring revenue models with global reach are likely to attract further investor attention, while sector incumbents may need to accelerate digital transformation and localization to remain competitive. Watch for increased M&A activity as well-capitalized players seek to replicate this growth trajectory.